Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 673193, 15 pages
Review Article

Evaluation of the Add-On Effect of Chinese Patent Medicine for Patients with Stable or Unstable Angina: A Systematic Review and Meta-Analysis

1Division of Epidemiology, JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Prince of Wales Hospital, 4/F School of Public Health Building, Shatin, New Territories, Hong Kong
2Shenzhen Municipal Key Laboratory for Health Risk Analysis, Shenzhen Research Institute, The Chinese University of Hong Kong, 10 Yuexing Erdao, Nanshan District, Shenzhen, Guangdong 518000, China
3The Hong Kong Branch of the Chinese Cochrane Centre, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong

Received 28 April 2013; Revised 8 October 2013; Accepted 15 October 2013

Academic Editor: Lixing Lao

Copyright © 2013 Chen Mao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chinese herbal medicine (CHM) has been widely used as an adjunct to western medicine in treating angina in China. We carried out this systematic review to evaluate the effectiveness of CHM on top of western medicine for angina. This meta-analysis included 46 randomized control trials with 4212 patients. For trials that included stable angina patients, the CHM group had significant lower incidence of total heart events (relative risk , 95% confidence interval (CI) 0.33–0.78), myocardial infarction ( , 95% CI 0.14–0.72), heart failure ( , 95% CI 0.15–0.91), and angina ( , 95% CI 0.30–0.71) than that of control group. For trials that included unstable angina patients, CHM led to significantly lower occurrence of total heart events ( , 95% CI 0.32–0.66), myocardial infarction ( , 95% CI 0.26–0.54), and angina ( , 95%CI 0.26–0.51). Likewise, for trials that included stable or unstable angina patients, the rates of myocardial infarction ( , 95% CI 0.17–0.68) and angina ( , 95% CI 0.30–0.70) in CHM group were significantly lower than that in control group. In conclusion, CHM is very likely to be able to improve the survival of angina patients who are already receiving western medicine.